Kestra Medical Technologies, Ltd. $KMTS Shares Acquired by Next Century Growth Investors LLC

Next Century Growth Investors LLC grew its holdings in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) by 154.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 465,845 shares of the company’s stock after acquiring an additional 282,832 shares during the quarter. Next Century Growth Investors LLC owned 0.80% of Kestra Medical Technologies worth $12,354,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Brown Brothers Harriman & Co. boosted its holdings in Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after acquiring an additional 656 shares in the last quarter. Rhumbline Advisers boosted its holdings in Kestra Medical Technologies by 7.3% in the third quarter. Rhumbline Advisers now owns 12,925 shares of the company’s stock worth $307,000 after acquiring an additional 874 shares in the last quarter. Farther Finance Advisors LLC acquired a new stake in Kestra Medical Technologies in the fourth quarter worth about $31,000. Police & Firemen s Retirement System of New Jersey boosted its holdings in Kestra Medical Technologies by 34.6% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock worth $144,000 after acquiring an additional 1,392 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in Kestra Medical Technologies by 148.9% in the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after acquiring an additional 1,638 shares in the last quarter.

Insider Transactions at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $20.96, for a total value of $314,400.00. Following the completion of the transaction, the insider directly owned 334,786 shares of the company’s stock, valued at approximately $7,017,114.56. The trade was a 4.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 45,000 shares of company stock valued at $919,050 over the last three months. Insiders own 3.60% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. BTIG Research reissued a “buy” rating and issued a $32.00 price target on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. The Goldman Sachs Group decreased their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $27.40.

Kestra Medical Technologies Trading Up 3.5%

Kestra Medical Technologies stock opened at $20.85 on Friday. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.15. Kestra Medical Technologies, Ltd. has a 52 week low of $13.25 and a 52 week high of $30.00. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -5.27 and a beta of 0.83. The stock has a 50-day moving average price of $20.70 and a 200 day moving average price of $23.10.

Kestra Medical Technologies (NASDAQ:KMTS) last released its earnings results on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The firm had revenue of $24.55 million for the quarter. Kestra Medical Technologies’s quarterly revenue was up 62.7% on a year-over-year basis. Sell-side analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.34 EPS for the current year.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.